Literature DB >> 23458718

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Inga Koneczny1, Judith Cossins, Angela Vincent.   

Abstract

MuSK myasthenia gravis is a rare, severe autoimmune disease of the neuromuscular junction, only identified in 2001, with unclear pathogenic mechanisms. In this review we describe the clinical aspects that distinguish MuSK MG from AChR MG, review what is known about the role of MuSK in the development and function of the neuromuscular junction, and discuss the data that address how the antibodies to MuSK lead to neuromuscular transmission failure.
© 2013 Anatomical Society.

Entities:  

Keywords:  AChR; DOK7; IgG4; LRP4; MG; RAPSN; muscle-specific tyrosine kinase; myasthenia gravis; neuromuscular transmission; quantal content

Mesh：

Substances：

Year:  2013        PMID： 23458718      PMCID： PMC3867884          DOI： 10.1111/joa.12034

Source DB:  PubMed          Journal:  J Anat        ISSN： 0021-8782            Impact factor:   2.610


  87 in total

1.  Patterning of muscle acetylcholine receptor gene expression in the absence of motor innervation.

Authors:  X Yang; S Arber; C William; L Li; Y Tanabe; T M Jessell; C Birchmeier; S J Burden
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

2.  Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis.

Authors:  Y Nemoto; S Kuwabara; S Misawa; N Kawaguchi; T Hattori; M Takamori; A Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

3.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

4.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis.

Authors:  D A Compston; A Vincent; J Newsom-Davis; J R Batchelor
Journal:  Brain       Date:  1980-09       Impact factor: 13.501

Review 5.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

6.  Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.

Authors:  Marco Morsch; Stephen W Reddel; Nazanin Ghazanfari; Klaus V Toyka; William D Phillips
Journal:  Exp Neurol       Date:  2012-07-10       Impact factor: 5.330

7.  Clinical and experimental features of MuSK antibody positive MG in Japan.

Authors:  K Ohta; K Shigemoto; A Fujinami; N Maruyama; T Konishi; M Ohta
Journal:  Eur J Neurol       Date:  2007-09       Impact factor: 6.089

8.  Crosslinking of proteins in acetylcholine receptor-rich membranes: association between the beta-subunit and the 43 kd subsynaptic protein.

Authors:  S J Burden; R L DePalma; G S Gottesman
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

9.  Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice.

Authors:  M Gautam; P G Noakes; J Mudd; M Nichol; G C Chu; J R Sanes; J P Merlie
Journal:  Nature       Date:  1995-09-21       Impact factor: 49.962

10.  MuSK controls where motor axons grow and form synapses.

Authors:  Natalie Kim; Steven J Burden
Journal:  Nat Neurosci       Date:  2007-12-16       Impact factor: 24.884
View more
  18 in total

Review 1.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 2.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

Review 3.  Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis.

Authors:  Rebecca L Hurst; Clifton L Gooch
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

Review 4.  Novel pathophysiological insights in autoimmune myasthenia gravis.

Authors:  Gianvito Masi; Kevin C O'Connor
Journal:  Curr Opin Neurol       Date:  2022-08-04       Impact factor: 6.283

Review 5.  Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.

Authors:  Fiammetta Vanoli; Renato Mantegazza
Journal:  Neurotherapeutics       Date:  2022-02-14       Impact factor: 6.088

6.  Small Quaternary Inhibitors K298 and K524: Cholinesterases Inhibition, Absorption, Brain Distribution, and Toxicity.

Authors:  Jana Zdarova Karasova; Milos Hroch; Kamil Musilek; Kamil Kuca
Journal:  Neurotox Res       Date:  2015-12-08       Impact factor: 3.911

Review 7.  The emerging role of the sympathetic nervous system in skeletal muscle motor innervation and sarcopenia.

Authors:  Osvaldo Delbono; Anna Carolina Zaia Rodrigues; Henry Jacob Bonilla; Maria Laura Messi
Journal:  Ageing Res Rev       Date:  2021-02-18       Impact factor: 10.895

8.  Clinical delineation of myasthenia gravis in the Kingdom of Bahrain.

Authors:  Mohamed F Binfalah; Hussein H Alhafnawi; Ahmed A Jaradat; Eslam Shosha; Ali J Alhilly; Firas K Al Nidawi; Mariam M Alhammadi; Moiz O Bakhiet; Fatema M Abdulla
Journal:  Neurosciences (Riyadh)       Date:  2022-01       Impact factor: 0.735

9.  Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis.

Authors:  Mariapaola Marino; Flavia Scuderi; Daniela Samengo; Giorgia Saltelli; Maria Teresa Maiuri; Chengyong Shen; Lin Mei; Mario Sabatelli; Giovambattista Pani; Giovanni Antonini; Amelia Evoli; Emanuela Bartoccioni
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

10.  Injection of a soluble fragment of neural agrin (NT-1654) considerably improves the muscle pathology caused by the disassembly of the neuromuscular junction.

Authors:  Stefan Hettwer; Shuo Lin; Stefan Kucsera; Monika Haubitz; Filippo Oliveri; Ruggero G Fariello; Markus A Ruegg; Jan W Vrijbloed
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.